VNZ/TEZ/D-IVA

DRUG4 trials

Sponsors

Vertex Pharmaceuticals Incorporated

Conditions

Cystic Fibrosis

Phase 1

A Study of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) in Healthy Adult Panelists

CompletedNCT06299696

Vertex Pharmaceuticals IncorporatedCystic Fibrosis

Start: 2024-03-26End: 2024-04-16Updated: 2024-05-16

A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)

CompletedNCT06299709

Vertex Pharmaceuticals IncorporatedCystic Fibrosis

Start: 2024-03-13End: 2024-05-23Updated: 2025-09-26

Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants

CompletedNCT07349394

Vertex Pharmaceuticals IncorporatedCystic Fibrosis

Start: 2026-01-12End: 2026-03-12Updated: 2026-04-02

Phase 3

Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older

Enrolling by invitationNCT05844449

Vertex Pharmaceuticals IncorporatedCystic Fibrosis

Start: 2023-08-11End: 2029-07-30Target: 174Updated: 2026-04-29

Related Papers

Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial.

2025-01-0221 citations